loading...| Preferred Name |
Metformin Hydrochloride |
|
| Synonyms |
|
|
| Definitions |
The hydrochloride salt of the biguanide metformin with antihyperglycemic and potential antineoplastic activities. Metformin inhibits complex I (NADPH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain, thereby increasing the cellular AMP to ATP ratio and leading to activation of AMP-activated protein kinase (AMPK) and regulating AMPK-mediated transcription of target genes. This eventually prevents hepatic gluconeogenesis, enhances insulin sensitivity and fatty acid oxidation and ultimately leads to a decrease in glucose levels. Metformin may exert antineoplastic effects through AMPK-mediated or AMPK-independent inhibition of mammalian target of rapamycin (mTOR), which is up-regulated in many cancer tissues. Furthermore, this agent also inhibits tumor cell migration and invasion by inhibiting matrix metalloproteinase-9 (MMP-9) expression which is mediated through the suppression of transcription activator protein-1 (AP-1) activation. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C29251 |
|
| ALT_DEFINITION |
A drug used to treat diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. It decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body's use of the glucose. Glucophage is a type of antidiabetic agent. |
|
| CAS_Registry |
1115-70-4 |
|
| Chemical_Formula |
C4H11N5.HCl |
|
| code |
C29251 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
The hydrochloride salt of the biguanide metformin with antihyperglycemic and potential antineoplastic activities. Metformin inhibits complex I (NADPH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain, thereby increasing the cellular AMP to ATP ratio and leading to activation of AMP-activated protein kinase (AMPK) and regulating AMPK-mediated transcription of target genes. This eventually prevents hepatic gluconeogenesis, enhances insulin sensitivity and fatty acid oxidation and ultimately leads to a decrease in glucose levels. Metformin may exert antineoplastic effects through AMPK-mediated or AMPK-independent inhibition of mammalian target of rapamycin (mTOR), which is up-regulated in many cancer tissues. Furthermore, this agent also inhibits tumor cell migration and invasion by inhibiting matrix metalloproteinase-9 (MMP-9) expression which is mediated through the suppression of transcription activator protein-1 (AP-1) activation. |
|
| Display_Name |
Metformin Hydrochloride |
|
| FDA_UNII_Code |
786Z46389E |
|
| Has_Free_Acid_Or_Base_Form | ||
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C173383 http://purl.obolibrary.org/obo/NCIT_C173381 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Metformin Hydrochloride |
|
| Legacy Concept Name |
Metformin_Hydrochloride |
|
| Maps_To |
Metformin Hydrochloride |
|
| NCI_Drug_Dictionary_ID |
593641 |
|
| NSC Number |
91485 |
|
| PDQ_Closed_Trial_Search_ID |
593641 |
|
| PDQ_Open_Trial_Search_ID |
593641 |
|
| Preferred_Name |
Metformin Hydrochloride |
|
| prefixIRI |
NCIT:C29251 |
|
| prefLabel |
Metformin Hydrochloride |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C0770893 |
|
| subClassOf |